SIGA Technologies Q3 2026 revenue falls to $1.3M
A special cash dividend of $0.60 per share was paid April 23, 2026, to shareholders of record at the close of business on April 7, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
SIGA Technologies reported total revenue of $1.3 million for the three months ended September 30, 2026, compared with $2.6 million in the same 2025 period. Product sales were $0.2 million versus $0.9 million, and the quarterly net loss was $2.9 million versus $6.4 million. For the nine months, total revenue was $48.6 million versus $90.8 million, while net income was $6.1 million versus $28.7 million; operating income was $2.1 million versus $33.2 million. Cash and cash equivalents were $116,380,386 as of September 30, 2026, compared with $154,966,414 as of December 31, 2025.
Chief Executive Officer Diem Nguyen said SIGA continues to work with the U.S. Government toward a new TPOXX procurement contract and is pursuing opportunities with other international governments. The company recently announced a $15 million contract with the Canadian Department of National Defence. Executive Vice President and Chief Scientific Officer Dennis Hruby, Ph.D., will retire effective November 9, 2026, after more than 30 years with SIGA and will continue in an advisory capacity.
1 point · 0 major0 major · 3 points
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQuarterly net loss narrowed to $2.9 million from $6.4 million.
Negative
- Moderate pointNine-month total revenue was $48.6 million, versus $90.8 million in 2025.
- Moderate pointNine-month net income was $6.1 million, versus $28.7 million in 2025.
- Minor pointQuarterly total revenue was $1.3 million, versus $2.6 million in 2025.
Filing Explained
A $0.60-per-share cash dividend had been paid by April 23, 2026; it was a completed distribution, not a new commitment.
This 8-K furnishes SIGA’s results release for the quarter ended
At
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Total revenue, three months ended September 30, 2026: $1.3 million
Net loss, three months ended September 30, 2026: $2.9 million
Total revenue, nine months ended September 30, 2026: $48.6 million
+4 more
7 metrics
Total revenue, three months ended September 30, 2026
$1.3 million
Compared with $2.6 million for the same 2025 period
Net loss, three months ended September 30, 2026
$2.9 million
Compared with a $6.4 million net loss for the same 2025 period
Total revenue, nine months ended September 30, 2026
$48.6 million
Compared with $90.8 million for the same 2025 period
Net income, nine months ended September 30, 2026
$6.1 million
Compared with $28.7 million for the same 2025 period
Cash and cash equivalents
$116,380,386
As of September 30, 2026; compared with $154,966,414 as of December 31, 2025
Canadian Department of National Defence contract
$15 million
Contract recently announced by SIGA
Special cash dividend per share
$0.60 per share
Paid April 23, 2026
Key Terms
Deferred IV TPOXX® revenue, weighted average shares outstanding, deferred tax asset, net
3 terms
Deferred IV TPOXX® revenue financial
"Deferred IV TPOXX® revenue"
deferred tax asset, net financial
"Deferred tax asset, net"
Earnings Snapshot
Total revenue, three months ended September 30: $1.3 million
Three and nine months ended September 30, 2026
Total revenue, three months ended September 30
$1.3 million
Down from $2.6 million in the same 2025 period
Net loss, three months ended September 30
$2.9 million
Narrowed from $6.4 million in the same 2025 period
Total revenue, nine months ended September 30
$48.6 million
Down from $90.8 million in the same 2025 period
Net income, nine months ended September 30
$6.1 million
Compared with $28.7 million in the same 2025 period
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were SIGA's third-quarter 2026 revenue and net loss?
SIGA reported total revenue of $1.3 million and a net loss of $2.9 million for the three months ended September 30, 2026. For the same 2025 period, total revenue was $2.6 million and net loss was $6.4 million.
What were SIGA's results for the nine months ended September 30, 2026?
SIGA reported $48.6 million in total revenue and net income of $6.1 million for the nine months ended September 30, 2026, compared with $90.8 million in revenue and $28.7 million in net income for the same period in 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 9, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission file number)
|
(I.R.S. employer identification no.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip code)
|
Registrant’s telephone number, including area code: (212 )
672-9100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition.
|
On November 9, 2026, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the
quarter ended September 30, 2026.
Pursuant to General Instruction B.2 of Form 8-K, the information contained in, or incorporated into, this Item 2.02, including the Press Release, is
being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by
reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.
The full text of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01. |
Financial Statements and Exhibits.
|
| (d) |
The following exhibits are included in this report:
|
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Earnings Press Release issued on November 9, 2026.
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
|
SIGA TECHNOLOGIES, INC.
|
||
|
By:
|
/s/ Daniel J. Luckshire
|
|
|
Name:
|
Daniel J. Luckshire
|
|
|
Title:
|
Chief Financial Officer
|
|
|
Date: November 9, 2026
|
||
Exhibit 99.1
 |
 |
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2026
| • |
Awarded $15 Million Procurement Contract from Canadian Department of National Defence for Oral TPOXX in October
|
| • |
Corporate Update Conference Call Today at 4:30 PM ET
|
NEW YORK, November 9, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company,
today reported financial results for the three and nine months ended September 30, 2026.
“While we continue to work with the U.S. Government toward a new TPOXX procurement contract, our international business remains an important
part of our strategy,” stated Diem Nguyen, Chief Executive Officer. “We recently announced a $15 million contract with the Canadian Department of National Defence, a longstanding customer, and are actively pursuing opportunities with other
international governments to further diversify our customer base over time.”
Summary Financial Results
|
($ in millions, except
per share amounts)
|
Three Months
Ended September 30
|
Nine Months
Ended September 30
|
||||||||||||||
|
2026
|
2025
|
2026
|
2025
|
|||||||||||||
|
Product sales (1)
|
$
|
0.2
|
$
|
0.9
|
$
|
41.6
|
$
|
85.8
|
||||||||
|
Total revenues (2)
|
$
|
1.3
|
$
|
2.6
|
$
|
48.6
|
$
|
90.8
|
||||||||
|
Operating (loss)/income(3) (4)
|
$
|
(6.5
|
)
|
$
|
(10.2
|
)
|
$
|
2.1
|
$
|
33.2
|
||||||
|
(Loss)/income before income taxes(3)
|
$
|
(5.5
|
)
|
$
|
(8.4
|
)
|
$
|
5.3
|
$
|
38.3
|
||||||
|
Net (loss)/income
|
$
|
(2.9
|
)
|
$
|
(6.4
|
)
|
$
|
6.1
|
$
|
28.7
|
||||||
|
Diluted (loss) / income per share
|
$
|
(0.04
|
)
|
$
|
(0.09
|
)
|
$
|
0.09
|
$
|
0.40
|
||||||
|
(1)
|
Includes supportive services related to product sales.
|
|
(2)
|
Includes research and development revenues.
|
|
(3)
|
Operating (loss)/income excludes, and (loss)/income before income taxes includes, other
income. Both line items exclude the impact of income taxes.
|
|
(4)
|
Differences in operating (loss)/income margin between periods reflect different product mixes in those periods.
|
|
|
Year-to-Date Business and Operational Activity
| • |
In October, the Canadian Department of National Defence (CDND) awarded a contract to SIGA for the procurement of oral
TPOXX. The contract provides for the purchase of up to approximately $15 million of oral TPOXX by March 31, 2031, of which approximately $9 million represents firm commitments over the first three years of the contract and approximately
$6 million is subject to option exercise by the CDND.
|
| • |
For the nine months ended September 30, 2026, the Company delivered approximately $13 million of oral TPOXX to two international customers.
|
| • |
For the nine months ended September 30, 2026, the Company delivered approximately $26
million of IV TPOXX to the U.S. Strategic National Stockpile (SNS) under the 19C contract, fulfilling the final procurement order under that contract.
|
Year-to-Date Capital Management Activity
On March 26, 2026, a special cash dividend of $0.60 per share was declared, and was paid on April 23, 2026, to shareholders of record at the
close of business on April 7, 2026.
Retirement of Chief Scientific Officer
Dennis Hrubry, Ph.D., Executive Vice President and Chief Scientific Officer, will retire effective today, concluding more than 30 years with
the Company. Following his retirement, Dr. Hruby will continue to support the Company in an advisory capacity.
Conference Call and Webcast
SIGA will host a conference call and webcast to provide a business update today, Monday, November 9, 2026, at 4:30 P.M. ET.
Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A live webcast
of the call will also be available on the Company's website at www.siga.com in the Investor Relations section of the website. Please log in approximately 5-10 minutes prior to the scheduled start time.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international
callers and using Conference ID: 1130564. The archived webcast will be available in the Investor Relations section of the Company's website.
|
|
ABOUT SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and
prevent infectious diseases. With a primary focus on smallpox, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships
with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including statements relating to SIGA’s future business performance and plans. Forward-looking statements include statements regarding our future financial position, business strategy, plans and objectives of management for future
operations, and delivering products to domestic and international customers under procurement contracts. The words “may,” “continue,” “estimate,” “intend,” “plan,” “will,” “believe,” “project,” “expect,” “seek,” “anticipate,” “could,” “should,”
“target,” “goal,” “potential” and similar expressions may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Such forward-looking statements are subject to various
known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those anticipated by
such forward-looking statements due to a number of factors, some of which are beyond SIGA’s control, including, but not limited to, (i) the risk that SIGA is not able to secure in a timely manner additional new contracts with the U.S. Government to
substantially maintain or expand the U.S. Government stockpile of TPOXX®, (ii) the risk that SIGA may not complete the remaining performance under the 19C BARDA Contract with the U.S. Biomedical Advanced Research and Development Authority on
schedule or in accordance with contractual terms, (iii) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX® internationally, (iv) the risk that potential
products, including potential alternative uses or formulations of TPOXX® that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (v) the risk that target timing for
deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by the actions, or inaction, of contract manufacturing organizations, or other vendors, within the supply chain, or due to coordination
activities between the customer and supply chain vendors, (vi) the risk that SIGA or its collaborators will not obtain or maintain appropriate or necessary governmental approvals to market these or other potential products or uses, (vii) the risk
that any challenge to SIGA’s patent and other property rights, if adversely determined, could affect SIGA’s business and, even if determined favorably, could be costly, (viii) the risk that regulatory requirements applicable to SIGA’s products may
result in the need for further or additional testing or documentation that will delay or prevent SIGA from seeking, obtaining or maintaining needed approvals to market these products, (ix) the risk that changes in domestic or foreign economic and
market conditions may affect SIGA’s ability to advance its research or may affect its products adversely, (x) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, on SIGA’s businesses,
(xi) the impacts of significant recent shifts in trade policies, including the imposition of tariffs, retaliatory tariff measures, and subsequent modifications or suspensions thereof, and market reactions to such policies and resulting trade
disputes, (xii) the risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX®, causing delays in SIGA’s research and development activities, causing delays or the re-allocation of funding in connection with SIGA’s government contracts,
or diverting the attention of government staff overseeing SIGA’s government contracts, (xiii) risks associated with actions or uncertainties surrounding the U.S. debt ceiling, or changes in the U.S. political environment, and (xiv) the risk that the
U.S. or foreign governments' responses (including inaction) to national or global economic conditions or infectious diseases, are ineffective and may adversely affect SIGA’s business, as well as the risks and uncertainties included in Item 1A “Risk
Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025 and SIGA's subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's
website at http://www.sec.gov. All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or
circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Investor and Media Contact
Suzanne Harnett
sharnett@siga.com
|
|
SIGA TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
As of
|
September 30,
2026
|
December 31,
2025
|
|||||||
|
ASSETS
|
||||||||
|
Current assets
|
||||||||
|
Cash and cash equivalents
|
$
|
116,380,386
|
$
|
154,966,414
|
||||
|
Accounts receivable
|
2,016,213
|
3,263,736
|
||||||
|
Inventory
|
41,594,073
|
49,054,873
|
||||||
|
Prepaid expenses and other current assets
|
5,547,353
|
5,571,841
|
||||||
|
Total current assets
|
165,538,025
|
212,856,864
|
||||||
|
Property, plant and equipment, net
|
1,376,079
|
1,090,824
|
||||||
|
Deferred tax asset, net
|
4,706,158
|
4,428,519
|
||||||
|
Goodwill
|
898,334
|
898,334
|
||||||
|
Other assets
|
129,507
|
192,893
|
||||||
|
Total assets
|
$
|
172,648,103
|
$
|
219,467,434
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities
|
||||||||
|
Accounts payable
|
$
|
480,572
|
$
|
824,522
|
||||
|
Accrued expenses and other current liabilities
|
6,222,914
|
6,520,057
|
||||||
|
Deferred IV TPOXX® revenue
|
—
|
10,240,000
|
||||||
|
Income tax payable
|
34,123
|
408,000
|
||||||
|
Total current liabilities
|
6,737,609
|
17,992,579
|
||||||
|
Other liabilities
|
2,656,647
|
2,653,283
|
||||||
|
Total liabilities
|
9,394,256
|
20,645,862
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity
|
||||||||
|
Common stock ($.0001 par value, 600,000,000 shares authorized, 71,855,015 and 71,611,302, issued and
outstanding at September 30, 2026 and December 31, 2025, respectively)
|
7,185
|
7,161
|
||||||
|
Additional paid-in capital
|
244,109,230
|
241,885,214
|
||||||
|
Accumulated deficit
|
(80,862,568
|
)
|
(43,070,803
|
)
|
||||
|
Total stockholders’ equity
|
163,253,847
|
198,821,572
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
172,648,103
|
$
|
219,467,434
|
||||
|
|
SIGA TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED)
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
|
2026
|
2025
|
2026
|
2025
|
|||||||||||||
|
Revenues
|
||||||||||||||||
|
Product sales and supportive services
|
$
|
233,689
|
$
|
889,748
|
$
|
41,641,900
|
$
|
85,835,855
|
||||||||
|
Research and development
|
1,083,276
|
1,730,252
|
6,919,898
|
4,944,963
|
||||||||||||
|
Total revenues
|
1,316,965
|
2,620,000
|
48,561,798
|
90,780,818
|
||||||||||||
|
Operating expenses
|
||||||||||||||||
|
Cost of sales and supportive services
|
575,660
|
1,002,083
|
21,077,729
|
26,714,283
|
||||||||||||
|
Selling, general and administrative
|
4,621,909
|
4,786,511
|
14,443,914
|
15,949,749
|
||||||||||||
|
Research and development
|
2,639,444
|
7,053,985
|
10,975,788
|
14,914,895
|
||||||||||||
|
Total operating expenses
|
7,837,013
|
12,842,579
|
46,497,431
|
57,578,927
|
||||||||||||
|
Operating (loss)/income
|
(6,520,048
|
)
|
(10,222,579
|
)
|
2,064,367
|
33,201,891
|
||||||||||
|
Other income, net
|
1,037,470
|
1,866,693
|
3,261,847
|
5,143,981
|
||||||||||||
|
(Loss)/Income before income taxes
|
(5,482,578
|
)
|
(8,355,886
|
)
|
5,326,214
|
38,345,872
|
||||||||||
|
Benefit/(Provision) for income taxes
|
2,589,514
|
1,990,067
|
789,904
|
(9,636,811
|
)
|
|||||||||||
|
Net and comprehensive (loss)/income
|
$
|
(2,893,064
|
)
|
$
|
(6,365,819
|
)
|
$
|
6,116,118
|
$
|
28,709,061
|
||||||
|
Basic (loss)/income per share
|
$
|
(0.04
|
)
|
$
|
(0.09
|
)
|
$
|
0.09
|
$
|
0.40
|
||||||
|
Diluted (loss)/income per share
|
$
|
(0.04
|
)
|
$
|
(0.09
|
)
|
$
|
0.09
|
$
|
0.40
|
||||||
|
Weighted average shares outstanding: basic
|
71,849,132
|
71,604,956
|
71,751,272
|
71,499,984
|
||||||||||||
|
Weighted average shares outstanding: diluted
|
71,849,132
|
71,604,956
|
71,895,843
|
71,801,188
|
||||||||||||